At the moment, dostarlimab has been approved in the United States for the treatment of dMMR recurrent or advanced endometrial cancer as a standalone therapy. This approval is specifically for cases where the cancer has worsened or progressed after previous treatment with a platinum-containing regimen. This approval is valid until June 6, 2023.